29.8.2025 07:15:00 CEST | Thor Medical ASA | Half yearly financial reports and
audit reports / limited reviews

Oslo, 29 August 2025: Thor Medical ASA, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, today announced
interim results for the first half year 2025. The company is still in an early
commercial phase, with the results and operating cash flow reflecting the start
of construction of AlphaOne, the company's first commercial plant for production
of high-quality radioisotopes for use in novel cancer treatments.

The development of new targeted alpha therapies (TAT) continued to attract a lot
of interest in the cancer community and opens large market opportunities for us
Thor Medical as a leading supplier of thorium-228 to power new and effective
cancer treatments. 

Achievements in the first half of 2025 include:

 * Final investment decision for AlphaOne taken